Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Current assets
Cash and cash equivalents	$ 4,909	$ 1,535
Prepaid expenses, deposits and other	414	660
Clinical trial deposit	205	1,075
Total current assets	5,528	3,270
Property and equipment, net	674	709
Total assets	6,202	3,979
Current liabilities
Accounts payable and accrued liabilities	2,207	2,784
Related party payables	52	298
Total current liabilities	2,259	3,082
Milestone payment liability	186	166
Total liabilities	2,445	3,248
Stockholders’ equity
Common stock Authorized 75,000 shares at June 30, 2024 (June 30, 2023 - 75,000), $0.001 par value Issued and outstanding 55,305 issued at June 30, 2024 (June 30, 2023 1,692)	55	2
Additional paid-in capital	153,305	141,438
Accumulated deficit	(159,876)	(151,375)
Accumulated other comprehensive income	21	21
Total stockholders’ equity	3,757	731
Total liabilities and stockholders’ equity	6,202	3,979
Preferred Stock Series A
Stockholders’ equity
Preferred stock	279	279
Preferred Stock Series C
Stockholders’ equity
Preferred stock	$ 9,973	$ 10,366